This is the Drug That Could Kick Regeneron's Stock Into Gear Post author:Sam Post published:December 13, 2017 Post category:BioPharma Regeneron shares have made little headway since the disappointing launch of Praluent in 2015. Source: BioSpace You Might Also Like AEterna Zentaris Announces Presentation Regarding Macrilen At 99th Annual Meeting Of March 2, 2017 John Wiley & Sons, Inc. Announces As New EVP Of Publishing Business October 12, 2017 FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Phospholipase 2G6 (P… November 1, 2017
FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Phospholipase 2G6 (P… November 1, 2017